JPS59172497A - Novel muramyl peptide derivative - Google Patents
Novel muramyl peptide derivativeInfo
- Publication number
- JPS59172497A JPS59172497A JP58047458A JP4745883A JPS59172497A JP S59172497 A JPS59172497 A JP S59172497A JP 58047458 A JP58047458 A JP 58047458A JP 4745883 A JP4745883 A JP 4745883A JP S59172497 A JPS59172497 A JP S59172497A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alanyl
- acetylmuramyl
- compound
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 title claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 3
- 235000004279 alanine Nutrition 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 28
- 208000015181 infectious disease Diseases 0.000 abstract description 10
- 239000004472 Lysine Substances 0.000 abstract description 8
- 125000006239 protecting group Chemical group 0.000 abstract description 8
- 230000000813 microbial effect Effects 0.000 abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
- 239000000194 fatty acid Substances 0.000 abstract description 4
- 229930195729 fatty acid Natural products 0.000 abstract description 4
- 150000004665 fatty acids Chemical group 0.000 abstract description 4
- 125000003277 amino group Chemical group 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 19
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- 238000000921 elemental analysis Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 150000002148 esters Chemical group 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- -1 t-butoxycarbonyl group Chemical group 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- COHDHYZHOPQOFD-UHFFFAOYSA-N arsenic pentoxide Chemical compound O=[As](=O)O[As](=O)=O COHDHYZHOPQOFD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- KPUNOVLMCQQCSK-UHFFFAOYSA-N diazomethane;ethoxyethane Chemical compound C=[N+]=[N-].CCOCC KPUNOVLMCQQCSK-UHFFFAOYSA-N 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- POCGVKPEBRPGOL-MFSWDZIZSA-N (2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-phenylbut-3-enoic acid Chemical compound C(C1=CC=CC=C1)=C[C@@H](O[C@@H]1[C@H](C(O)O[C@@H]([C@H]1O)CO)NC(C)=O)C(=O)O POCGVKPEBRPGOL-MFSWDZIZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000002820 allylidene group Chemical group [H]C(=[*])C([H])=C([H])[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- XGZVNVFLUGNOJQ-UHFFFAOYSA-N n,n-dimethylformamide;ethyl acetate Chemical compound CN(C)C=O.CCOC(C)=O XGZVNVFLUGNOJQ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は微生物感染予防・治療効果を有し。[Detailed description of the invention] The present invention has effects on preventing and treating microbial infections.
かつ優れた制癌効果が認められる新規ムラミルチペブチ
ド誘導体、更に詳しくは一般式(1)で示めされるムラ
ミルがペプチド誘導体に関する。The present invention relates to a novel muramyl tipebutide derivative which is also recognized to have an excellent anticancer effect, and more specifically to a peptide derivative of muramyl represented by the general formula (1).
(上記式中Alaはアラニンを意味し、Rは水素原子、
アルキル基又はアラルキル基を、nは1〜6の整数を+
AI及びA2は各々水素原子又は炭素原子数2〜80
の分枝を有することもある飽和もしくは不飽和脂肪酸残
基を意味する。)免疫アジュバント物質としてN−アセ
チルムラミル−L−アラニル−D−イソグルタミンが知
られているが、治療的、実用的観点からして微生物感染
防禦活性、抗腫瘍活性等の点で必ずしも満足すべきもの
でない。(In the above formula, Ala means alanine, R is a hydrogen atom,
an alkyl group or an aralkyl group, n is an integer of 1 to 6 +
AI and A2 each have a hydrogen atom or a carbon atom number of 2 to 80
refers to a saturated or unsaturated fatty acid residue which may have branching. ) N-acetylmuramyl-L-alanyl-D-isoglutamine is known as an immune adjuvant substance, but from a therapeutic and practical standpoint, it is not necessarily satisfactory in terms of microbial infection prevention activity, antitumor activity, etc. Not a kimono.
従って本発明者等は、微生物感染防禦活性。Therefore, the present inventors have determined that the activity of preventing microbial infection.
抗腫瘍活性を有する化合物について鋭意検討を試みた結
果、一般式(1)で示めされる化合物が優れた微生物感
染防禦活性、抗腫瘍活性を有すことを見出し本発明を完
成させた。As a result of intensive studies on compounds having antitumor activity, the present invention was completed by discovering that the compound represented by general formula (1) has excellent microbial infection prevention activity and antitumor activity.
本発明によって得られる化合物は、たとえば微生物感染
予防・治療剤、抗癌剤等として多くの疾病に用いること
ができる。The compounds obtained according to the present invention can be used for many diseases, for example, as agents for preventing and treating microbial infections, anticancer agents, and the like.
本発明化合物の効果は下記する通り。The effects of the compounds of the present invention are as follows.
(1)微生物感染防禦効果
本発明化合物の感染防禦効果を以下のごとき方法で求め
た。(1) Microbial infection prevention effect The infection prevention effect of the compound of the present invention was determined by the following method.
本発明化合物は500μg、/−のp、a、5(pH7
,4)溶液となるよう調製した。調製した薬剤液の0.
2−を5TD−ddYマウス(5週令)に皮下投与し、
ついで24時間後にE、 coliE77156を表1
に示す接種菌量で皮下感染した。効果判定は感染7日後
のマウス生存率(%)から求めた。その結果2表1で示
めされる通り本発明化合物は優れた感染防禦効果を呈し
た。The compound of the present invention was 500 μg, p, a, 5 (pH 7
, 4) Prepared to become a solution. 0.0 of the prepared drug solution.
2- was subcutaneously administered to 5TD-ddY mice (5 weeks old),
Then, 24 hours later, E. coli E77156 was detected in Table 1.
Subcutaneous infection was carried out using the inoculum amount shown in . Efficacy was determined from the mouse survival rate (%) 7 days after infection. As shown in Table 2, the compound of the present invention exhibited excellent infection prevention effects.
表I E、coli感染マウスに対する防禦効果(2
)抗腫瘍活性
B A L B/C雄マウマウスチルコラントレンで誘
発した線維肉腫細胞(Meth A ) 2 X 10
5個と試料をPBS pH7,4に懸濁し、同系のB
A L B / Gマウスの皮内に投与し、4週間後の
線維肉腫の増殖抑制効果を調べた。(表−2)毫完全腫
瘍増殖抑制マウス数/使用マウス数東聚 無処置群の
腫瘍重量を100とした時の割合
本発明化合物
本発明化合物−1:
N’−(6−0−ステアロイル−N−アセチルムラミル
−アラニル−D−イソグルタミニル)−リジン
本発明化合物−2=
l−アセチルーN6−(6−0−ステアロイル−N−ア
セチルムラミル−アラニル−D−イソグルタミニル)−
リジン
本発明化合物−8ニ
ーーステアロイル−N’−(N−アセチルムラミル−ア
ラニル−D−イソグルタミニル)−リジンメチルエステ
ル
本発明化合物−4=
一一アセチルーN’−(6−0−ステアロイル−N−ア
セチルムラミル−アラニル−D−イソグルタミニル)−
リジンメチルエステル本発明化合物(1)はたとえば2
式
()
(式中、R及びnは前記定義の通りであり2.zは通常
ペプチド合成に繁用されるアミン基の保護基1例えばハ
ロゲン原子、ニトロ基等の置換基を有することもあるベ
ンジルオキシカルボニル基が挙げられる。)で示される
化合物の保護基(Z)を脱離することにより、又保護基
を脱離したものに式A3−0H(l[)(式中r A3
は炭素原子数2〜30の分校を有することもある飽和又
は不飽和脂肪酸残基を意味する。)で示めされる化合物
の活性体9例えば活性エステル体、酸無水物体等を縮合
することにより得られる。又1式(It)に式(1)で
示めされる化合物の活性体1例えば酸クロライド体、活
性エステル体等を縮合し1次いで保護基を脱離すること
によっても得られる。Table I E, Protective effect on coli infected mice (2
) Antitumor activity BALB/C male mouse fibrosarcoma cells induced with tilcholanthrene (Meth A) 2 X 10
5 pieces and the sample were suspended in PBS pH 7.4, and the same type of B
It was administered intradermally to ALB/G mice, and the inhibitory effect on fibrosarcoma growth was examined 4 weeks later. (Table 2) Number of mice with completely suppressed tumor growth/Number of mice used Percentage when the tumor weight of the untreated group is taken as 100 Compound of the present invention Compound-1 of the present invention: N'-(6-0-stearoyl- N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine Compound of the present invention-2 = l-acetyl-N6-(6-0-stearoyl-N-acetylmuramyl-alanyl-D-isoglutaminyl)-
Lysine compound of the present invention -8-stearoyl-N'-(N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine methyl ester Compound of the present invention-4 = 1-acetyl-N'-(6-0-stearoyl-N- acetylmuramyl-alanyl-D-isoglutaminyl)-
Lysine methyl ester The compound (1) of the present invention is, for example, 2
Formula () (In the formula, R and n are as defined above, and 2. z is a protecting group for an amine group that is commonly used in peptide synthesis. It may have a substituent such as a halogen atom or a nitro group. By removing the protecting group (Z) of the compound represented by the formula A3-0H(l[) (in the formula r A3
means a saturated or unsaturated fatty acid residue which may have branches of 2 to 30 carbon atoms. ) can be obtained by condensing an active form 9 of the compound represented by, for example, an active ester form, an acid anhydride, etc. It can also be obtained by condensing an active form 1 of the compound represented by formula (1), such as an acid chloride form or an active ester form, with formula (It) and then removing the protective group.
式(II)に式(II)の活性エステル体を縮合する際
は。When condensing the active ester of formula (II) with formula (II).
有機塩基2例えばトリエチルアミン、N−メチルモルホ
リン、N−エチルモルホリン、N、N−ジメチルアミノ
ピリジン等および1−ヒドロキシベンゾトリアゾールの
共存下縮合反応をおこなうことが好ましい。更にはかく
して得られる式
()
(式中+ A3+ R及びnは前記定義の通り)と式(
II)の活性体9例えば活性エステル体、酸無水物体等
を縮合することによっても得られる。It is preferable to carry out the condensation reaction in the presence of an organic base 2 such as triethylamine, N-methylmorpholine, N-ethylmorpholine, N,N-dimethylaminopyridine, etc. and 1-hydroxybenzotriazole. Furthermore, the formula () obtained in this way (in the formula + A3+ R and n are as defined above) and the formula (
The activated form 9 of II) can also be obtained by condensing active esters, acid anhydrides, etc.
本発明化合物(I)の製造に使用する原料化合物。Raw material compound used for producing compound (I) of the present invention.
即ち式(n)で示めされる化合物は下記の方法に従って
製しうる。That is, the compound represented by formula (n) can be produced according to the following method.
即ち、N−アセチルムラミン酸に式
(式中、R,Z及びnは前記定義の通り)を縮合するこ
とによって達せられる。この縮合反応は一般にペプチド
合成で繁用されるカルボジイミド法、アイントップ法、
活性エステル法及ヒ酸無水物法等が採用しうる。That is, it can be achieved by condensing N-acetylmuramic acid with the formula (wherein R, Z and n are as defined above). This condensation reaction is generally carried out by the carbodiimide method, the Aintop method, which is often used in peptide synthesis.
An active ester method, an arsenic anhydride method, etc. can be adopted.
式(V)で示めされる化合物を製するには式(式中、Y
は通常のペプチド合成に繁用されるアミノ基の保護基9
例えばt−ブトキシカルボニル基やP−メトキシベンジ
ルオキシカルボニル基等が挙げられる。)に式
(式中、R及び2は前記定義の通り)を縮合し。To prepare a compound represented by formula (V), the formula (wherein Y
is an amino group protecting group 9 that is often used in ordinary peptide synthesis.
Examples include t-butoxycarbonyl group and P-methoxybenzyloxycarbonyl group. ) is condensed with the formula (wherein R and 2 are as defined above).
かくして得られる化合物を次いで適当な保護基の脱離条
件を採用し、保護基Yを脱離すれば得られる。The compound thus obtained can then be obtained by removing the protecting group Y using appropriate conditions for removing the protecting group.
式0)と(ロ))の縮合反応は、一般にペプチド合成で
繁用される前記の縮合方法を、又Yの脱離にはトリフル
オロ酢酸や塩酸/テトラヒドロ7ラン処理する方法が採
用しうる。For the condensation reaction of formulas 0) and (b)), the above-mentioned condensation method that is commonly used in peptide synthesis can be adopted, and for the elimination of Y, a method of trifluoroacetic acid or hydrochloric acid/tetrahydro 7 run treatment can be adopted. .
また、N−アセチルムラミン酸と式(V)の縮合反応の
際、N−アセチルムラミン酸の糖4及び6位水酸基をア
リリデン基9例えばベンジリデン、P−メトキシベンジ
リデン等で、糖1位水酸基をアラルキル基2例えばハロ
ゲン原子、二Fロ基もしくはメトキシ基等が一個以上が
置換することもあるベンジル基等で保護したものを採用
すれば縮合反応における副反応を減少しうるので望まし
い。In addition, during the condensation reaction of formula (V) with N-acetylmuramic acid, the hydroxyl groups at the 4th and 6th positions of the sugar of N-acetylmuramic acid are replaced with allylidene groups 9 such as benzylidene, P-methoxybenzylidene, etc., and the hydroxyl group at the 1st position of the sugar It is preferable to use an aralkyl group 2 protected by a benzyl group or the like, which may be substituted with one or more of a halogen atom, a diF 2 group, or a methoxy group, since side reactions in the condensation reaction can be reduced.
以下実施例及び参考例を挙げて説明する。The following description will be given with reference to examples and reference examples.
実施例1
一一ペンジルオキシ力ルボニルーリジンベンジルエステ
ルp−)ルエンスルホン酸塩8.959にテトラヒドロ
フラン90−を加える。水冷攪拌下、N−メチルモルホ
リン1.65i、t−ブチルオキシカルボニル−アラニ
ル−D−イソグルタミン4.76g、N−ヒドロキシサ
クシイミド1.9(l及びジシクロへキシルカルボジイ
ミド8.4(lを加え、30分後室温(こ戻す。反応液
中にゲル状物質が析出するためテトラヒドロフラン2Q
i、N、N−ジメチルホルムアミド20−をさらに加え
1晩攪拌反応する。析出するジシクロヘキシル尿素を濾
去、濾液を減圧濃縮する。残留物に100frLtの水
を加え析出する結晶を濾取2次いで5%クエン酸溶液、
水、5%炭酸水素ナトリウム溶液、水で順次洗浄後。Example 1 90% of tetrahydrofuran is added to 8.959% of 11penzyloxybenzylbenzyl ester p-)luenesulfonate. While cooling with water and stirring, add 1.65 i of N-methylmorpholine, 4.76 g of t-butyloxycarbonyl-alanyl-D-isoglutamine, 1.9 (l) of N-hydroxysuccinimide and 8.4 (l) of dicyclohexylcarbodiimide. , 30 minutes later, return to room temperature (return to room temperature). Because a gel-like substance precipitates in the reaction solution,
i,N,N-dimethylformamide 20- is further added and the reaction is stirred overnight. The precipitated dicyclohexylurea is filtered off, and the filtrate is concentrated under reduced pressure. Add 100frLt of water to the residue and collect the precipitated crystals by filtration.2 Then, add 5% citric acid solution,
After washing sequentially with water, 5% sodium bicarbonate solution, and water.
N、N−ジメチルホルムアミド−エーテル溶液力)ら再
結晶することにより一一ペンジルオキシ力ルボニルーN
6−(t−ブチルオキシカルボニル−アラニル−D−イ
ソグルタミンル)−1ノジンベンジルエステル7.1(
lを得る。融点175〜177℃(分解)。〔α尤5−
14.5°(C−1,6゜N、N−ジメチルホルムアミ
ド)。By recrystallizing from N,N-dimethylformamide-ether solution,
6-(t-Butyloxycarbonyl-alanyl-D-isoglutaminel)-1-nodine benzyl ester 7.1(
get l. Melting point 175-177°C (decomposed). [α 5-
14.5° (C-1,6°N, N-dimethylformamide).
元素分析値 Cs a H47N509計算値(2))
060.97. H7,07,N 10.46分
析値(%) C61,12,H6,98,N 10.
52上記化合物5.609をジクロルメタン30iに懸
濁し、水冷攪拌下トリフルオロ酢酸80mを加える。5
分後室温に戻し1時間反応後、減圧濃縮乾固する。残留
物をN、N−ジメチルホルムアミド45dに溶解し、水
冷攪拌下N−メチルモルホリンを加え中和する。この溶
液に次に示めす様にして得た1−α−0−ベンジル−4
,6−0−ベンジリデン−N−アセチルムラミン酸のN
−ヒドロキシコハク酸イミドエステルのN、N−ジメチ
ルホルムアミド溶液35−を加える。Elemental analysis value Cs a H47N509 calculated value (2))
060.97. H7,07,N 10.46 Analysis value (%) C61,12,H6,98,N 10.
52 The above compound 5.609 is suspended in 30 m of dichloromethane, and 80 m of trifluoroacetic acid is added while stirring while cooling with water. 5
After a few minutes, the mixture was returned to room temperature, reacted for 1 hour, and then concentrated to dryness under reduced pressure. The residue was dissolved in 45 d of N,N-dimethylformamide and neutralized by adding N-methylmorpholine while stirring while cooling with water. 1-α-0-benzyl-4 obtained as shown below is added to this solution.
, 6-0-benzylidene-N-acetylmuramic acid N
- Add 35- of a solution of hydroxysuccinimide ester in N,N-dimethylformamide.
(1−α−0−ベンジル−’1.6−0−ベンジリデン
ーN−アセチルムラミン酸3.58り、N−ヒドロキシ
コハク酸イミド0.96をテトラヒドロフランに溶解し
、水冷攪拌下ジシクロへキシルカルボジイミド1.72
9を加える。300分後室温戻し、5時間攪拌後、析出
したジシクロヘキシル尿素を濾去する。濾液を減圧濃縮
し得られた残留物を1−α−0−ベンジル−4,6−0
−ベンジリデン−N−アセチルムラミン酸のN−ヒドロ
キシコハク酸イミドエステルとして使用)
80分後、室温に戻し1晩反応する。反応液中に析出し
たゲルを濾取し、エーテル、95%エタノール洗浄する
ことにより7.3’lのl−べNf″
ンジルオキシカルボニル−r−(x−α−〇−ベンジル
ー4.6−0−ベンジリデン−N−アセチルムラミル−
アラニル−D−イソグルタミニル)−リジンベンジルエ
ステルを得る。融点236〜239℃(分解)。(3.58 parts of 1-α-0-benzyl-'1,6-0-benzylidene-N-acetylmuramic acid and 0.96 parts of N-hydroxysuccinimide were dissolved in tetrahydrofuran, and dicyclohexylcarbodiimide was dissolved under water-cooling and stirring. 1.72
Add 9. After 300 minutes, the mixture was returned to room temperature, and after stirring for 5 hours, the precipitated dicyclohexyl urea was filtered off. The filtrate was concentrated under reduced pressure and the resulting residue was converted to 1-α-0-benzyl-4,6-0
-Used as N-hydroxysuccinimide ester of benzylidene-N-acetylmuramic acid) After 80 minutes, the mixture was returned to room temperature and reacted overnight. The gel precipitated in the reaction solution was collected by filtration and washed with ether and 95% ethanol to obtain 7.3'l of l-benzyloxycarbonyl-r-(x-α-〇-benzyl-4.6 -0-benzylidene-N-acetylmuramyl-
Alanyl-D-isoglutaminyl)-lysine benzyl ester is obtained. Melting point 236-239°C (decomposed).
上記化合物7.8’lに60%酢酸溶液8〇−を加え1
時間沸騰水浴上で加熱する。放冷後。Add 80% of 60% acetic acid solution to 7.8'l of the above compound and add 1
Heat on a boiling water bath for an hour. After cooling.
減圧濃縮し得られた残留物に水150−を加え析出する
結晶を濾取する。次いでN、N−ジメチルホルムアミド
−酢酸エチルから再結晶し、白色結晶として5.619
の一一ペンジルオキシ力ルボニルーN’−(1−α−0
−ベンジル−N−アセチルムラミル−アラニル−D−イ
ソグルタミニル)−リジンベンジルエステルを得る。融
点222〜225°C(分解)。〔α)、+55.9゜
CG−0,9,N、N−ジメチルホルムアミド)。150 ml of water is added to the residue obtained by concentration under reduced pressure, and the precipitated crystals are collected by filtration. It was then recrystallized from N,N-dimethylformamide-ethyl acetate to yield 5.619 as white crystals.
11penzyloxycarbonylN'-(1-α-0
-benzyl-N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine benzyl ester is obtained. Melting point 222-225°C (decomposition). [α), +55.9°CG-0,9,N,N-dimethylformamide).
元素分析値 C47H62Ns Ot 4として計算値
(%) C60,87,H6,68,N 8.99分
析値(%> 060.19. H6,66、N 9
.28上記化合物0.509を酢酸2otnlに溶解し
。Elemental analysis value Calculated value (%) as C47H62Ns Ot 4 C60,87, H6,68, N 8.99 Analysis value (%> 060.19. H6,66, N 9
.. 28 0.509 of the above compound was dissolved in 2 otnl of acetic acid.
パラジウム黒存在下、水素気流中で還元反応をおこなう
。触媒を濾去、濾液を減圧濃縮し、残留物をセファデッ
クスLH−20ゲル濾過クロマトに付す。0.2M酢酸
溶液で溶出させ、精製後、凍結乾燥することにより白色
粉末としてH6−(N−アセチルムラミル−アラニル−
D−イソグルタミニル)−リジン0.219を得る。The reduction reaction is carried out in a hydrogen stream in the presence of palladium black. The catalyst was removed by filtration, the filtrate was concentrated under reduced pressure, and the residue was subjected to Sephadex LH-20 gel filtration chromatography. H6-(N-acetylmuramyl-alanyl-
0.219 of D-isoglutaminyl)-lysine is obtained.
実施例2
実施例1とほぼ同様に反応することにより一一ペンジル
オキシ力ルボニルーリジンメチルエステル塩酸塩11.
629とt−ブチルオキシカルボニル−アラニル−D−
イソグルタミン9.839から白色結晶として一一ペン
ジルオキシ力ルボニルーNE−(t−ブチルオキシカル
ボニル−D−イソグルタミニル)−リジンメチルエステ
ル10.919を得る。融点124〜126°C(分解
)。〔α〕Ll−13.6°(C−0,6゜N、N−ジ
メチルホルムアミド)。Example 2 By reacting in substantially the same manner as in Example 1, 11penzyloxycarbonyluridine methyl ester hydrochloride 11.
629 and t-butyloxycarbonyl-alanyl-D-
From isoglutamine 9.839, 11penzyloxycarbonyl-NE-(t-butyloxycarbonyl-D-isoglutaminyl)-lysine methyl ester 10.919 is obtained as white crystals. Melting point 124-126°C (decomposed). [α]Ll-13.6° (C-0,6°N, N-dimethylformamide).
元素分析値 C2a H4s Ns 09として計算値
(%) C56,65,H7,30,N 11.80
分析値(%) C56,61,H7,16,N 11
.62上記化合物10.099と1−α−0−ベンジル
−4,6−0−ベンジリデン−N−・アセチルムラミン
酸7.29gから白色粉末として一一ペンジルオキシ力
ルボニルーN5−(1−α−0−ベンジル−4,6−0
−ベンジリデン−N−ア七チルムラミルーアラニルーD
−イソグルタミニル)−リジンメチルエステル18.1
02を得る。融点235〜237°C(分解)。〔α)
、+59.9゜(0−0,4,N、N−ジメチルホルム
アミド)。Elemental analysis value C2a H4s Ns Calculated value (%) as 09 C56,65,H7,30,N 11.80
Analysis value (%) C56,61, H7,16, N 11
.. 62 From the above compound 10.099 and 7.29 g of 1-α-0-benzyl-4,6-0-benzylidene-N-acetylmuramic acid, 11penzyloxycarbonyl-N5-(1-α-0 -benzyl-4,6-0
-benzylidene-N-a7tylmuramyl-alanyl-D
-isoglutaminyl)-lysine methyl ester 18.1
Get 02. Melting point 235-237°C (decomposition). [α)
, +59.9° (0-0,4,N,N-dimethylformamide).
元素分析値 C4aH62NaO1r H20として計
算値(支)) C59,74,H6,68,N 8.
71分析値(%) G 59.44. H6,39
,N 8.74上記化合物18.102から白色結晶と
して一一ペンジルオキシ力ルボニルーN6−(1−α−
0−ベンジル−N−アセチルムラミル−アラニル−D−
イソグルタミニル)−リジンメチルエステル6.779
を得る。融点198〜199°C(分解)。(α)D
+64.6°(c−0,5,N、N−ジメチルホルムア
ミド)。Elemental analysis value C4aH62NaO1r Calculated value (support) as H20) C59,74,H6,68,N 8.
71 Analysis value (%) G 59.44. H6,39
,N 8.74 From the above compound 18.102, 11penzyloxycarbonylN6-(1-α-
0-Benzyl-N-acetylmuramyl-alanyl-D-
isoglutaminyl)-lysine methyl ester 6.779
get. Melting point 198-199°C (decomposed). (α)D
+64.6° (c-0,5,N,N-dimethylformamide).
元素分析直 C4t Hs s Na Ot 4として
計算値(支)) G 57.Ll、 H6,81,
N 9.78分析値じ) C57,18,H6,98
,N 9.65上記化合物1.50gから白色粉末とし
てN5−(N−アセチルムラミル−アラニル−D−イソ
グルタミニル)−リジンメチルエステルo、69りを得
る。融点88〜90’C(分解)。Direct elemental analysis Calculated value as C4t Hs Na Ot 4 (support)) G 57. Ll, H6,81,
N 9.78 analysis value same) C57,18, H6,98
, N 9.65 From 1.50 g of the above compound, N5-(N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine methyl ester o,69 is obtained as a white powder. Melting point 88-90'C (decomposed).
〔α)、+22.9°(C−1,1,水、2日後)。[α), +22.9° (C-1,1, water, 2 days later).
元素分析値 C25H4sNaOtr GHa’;OO
H・4H20とシテ計算値(%) C47,79,H
7,30,N 11.94分析値し) C47,62
,H7,21,N 11.73実施例8
N’−(N−アセチルムラミル−アラニル−D−イソグ
ルタミニル)−リジンメチルエステル0.649をN、
N−ジメチルホルムアミド1511L/に溶解する。水
冷攪拌下、ステアリン酸のN−ハイドロキシ−5−ノル
ボルネン−2,3−ジカルボキシイミド活性エステル0
゜49gI N−メチルモルホリン0.11−を加える
。30分後。Elemental analysis value C25H4sNaOtr GHa';OO
H・4H20 and shite calculation value (%) C47,79,H
7,30,N 11.94 analysis value) C47,62
, H7,21,N 11.73 Example 8 N'-(N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine methyl ester 0.649 with N,
Dissolve in 1511 L/N-dimethylformamide. Under water-cooled stirring, N-hydroxy-5-norbornene-2,3-dicarboximide active ester of stearic acid 0
Add 0.11 g of 49 g of N-methylmorpholine. 30 minutes later.
徐々に室温にもどし一晩攪拌反応する。反応液を減圧濃
縮し、残留物にエーテルを加え、析出する結晶を濾取す
る。これをシリカゲルクロマトグラフィーに付し、クロ
ロホルム−メタノール(9:1)で溶出させ精製1次い
でメタノール−エーテルから再結晶することによりl−
ステアロイルーN’−(N−アセチルムラミル−アラニ
ル−D−イソグルタミニル)−リジンメチルエステル0
.409を得る。融点187〜5
188.5°C(分解)。〔α〕。+18.8°(Cニ
ー1.2゜N、N−ジメチルホルムアミド−820−5
0/ 2 。Gradually return to room temperature and stir overnight for reaction. The reaction solution was concentrated under reduced pressure, ether was added to the residue, and the precipitated crystals were collected by filtration. This was purified by subjecting it to silica gel chromatography, eluting with chloroform-methanol (9:1), and then recrystallizing from methanol-ether.
Stearoyl N'-(N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine methyl ester 0
.. Get 409. Melting point 187-5 188.5°C (decomposed). [α]. +18.8° (C knee 1.2°N, N-dimethylformamide-820-5
0/2.
2日後)。2 days later).
元素分析値 G4aHsoNs013・2H20として
計算値(%) C56,19,H9,03,N 8.
97分析値(%) C56,35,H8,74,N
9.01実施例4
f−ベンジルオキシカルボニル−N6−(1−α−0−
ベンジル−N−アセチルムラミル−アラニル−D−イン
グルミニル)−リジンベンジルエステル5.007にピ
リジン400ml、 N、N−ジメチルホルムアミド5
0tnlを加え−15〜−10℃に冷却する。攪拌下ス
テアロイルクロライド6.489のクロロホルム溶液1
0−を徐々に加える。10分後さらにステアロイルクロ
ライド6.48りのクロロホルム溶液10−を加える。Elemental analysis value Calculated value (%) as G4aHsoNs013/2H20 C56,19,H9,03,N 8.
97 analysis value (%) C56,35,H8,74,N
9.01 Example 4 f-benzyloxycarbonyl-N6-(1-α-0-
Benzyl-N-acetylmuramyl-alanyl-D-ingluminyl)-lysine benzyl ester 5.007 to pyridine 400 ml, N,N-dimethylformamide 5
Add 0 tnl and cool to -15 to -10°C. Stirred stearoyl chloride 6.489 chloroform solution 1
Add 0- gradually. After 10 minutes, a chloroform solution of 6.48 parts of stearoyl chloride (10 parts) is added.
10分後、メタノール100−を加えた後1反応液を減
圧濃縮する。残留物に500−の水を加え析出する沈殿
を濾取する。乾燥後。After 10 minutes, 100 methanol was added and the reaction solution was concentrated under reduced pressure. Add 500ml of water to the residue and collect the precipitate by filtration. After drying.
クロロホルム200−に溶解し、ジアゾメタン−エーテ
ル溶液を加え9次に30分攪拌反応後。After dissolving in 200% of chloroform and adding diazomethane-ether solution, the mixture was stirred and reacted for 30 minutes.
反応液の黄色が消失するまで酢酸を加える。反応液を減
圧濃縮後、得られた残留物をシリカゲルクロマトグラフ
ィーに付し、クロロホルム−メタ/−ル(9:1)で溶
出させ精製し1次いでクロロホルム−エーテルから再結
晶することにより一一ペンジルオキシ力ルボニルーNE
−(1−α−0−ベンジル−6−0−ステアロイル−N
−アセチルムラミル−アラニル−D−イソグルタミニル
)−リジンベンジルエステル2.819を得る。融点2
00〜202°C(分解)。Add acetic acid until the yellow color of the reaction solution disappears. After concentrating the reaction solution under reduced pressure, the resulting residue was purified by silica gel chromatography and eluted with chloroform-metal (9:1), and then recrystallized from chloroform-ether to give 11-penzyloxy. Power Ruboni Lou NE
-(1-α-0-benzyl-6-0-stearoyl-N
-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine benzyl ester 2.819 is obtained. Melting point 2
00-202°C (decomposition).
〔α)、+35.2°(C−0,6,クロロホルム)0
元素分析値 c6sH9aNs01s・4H20として
計算値(%) C64,49,H8,07,N 6.
94分析値(%) G 64.26. H8,08
,N 7.20上記化合物2.50りを酢酸150fn
tに溶解し。[α), +35.2° (C-0,6, chloroform) 0
Elemental analysis value: Calculated value (%) as c6sH9aNs01s/4H20 C64,49,H8,07,N 6.
94 Analysis value (%) G 64.26. H8,08
, N 7.20 2.50 liters of the above compound was dissolved in acetic acid 150 fn
Dissolved in t.
パラジウム黒存在下水素気流中で還元反応をおこなう。The reduction reaction is carried out in a hydrogen stream in the presence of palladium black.
触媒を濾去、濾液を減圧濃縮し、残留物をセファデック
スLH−20ゲル濾過クロマトグラフィーに付す。0.
2M酢酸溶液で溶出させ、精製後、凍結乾燥することに
より白色粉末としてN6− (6−0−ステアロイル−
N−アセチルムラミル−アラニル−D−イソグルタミニ
ル)−リジン1.61gを得る。融点185〜187°
C(分解)。〔α〕、→−21.8°(C−0,5゜水
、3日後)
元素分析値 C45HtsNeO1s・CH#OOH・
H2Oとシテ計算値(%) G 56.00. H
8,77、N 8.71分析値(%) C55,99
,H8,76、N 8.76実施例5
実施例4とほぼ同様に反応することにより一一ペンジル
オキシ力ルボニルーN” (1−α−〇−ベンジルーN
−アセチルムラミル−アラニル−D−イングルタミニル
)−リジンメチルエステル1.509がらl−ペンジル
オキシ力ルボニ)’−NE−(1−(1−0−ヘ>シル
−6−0−ステアロイル−N−アセチルムラミル−アラ
ニル−D−イングルタミニル)−リジンメチルエステル
1.30りを得る。融点204〜205°C(分#)。The catalyst was removed by filtration, the filtrate was concentrated under reduced pressure, and the residue was subjected to Sephadex LH-20 gel filtration chromatography. 0.
N6- (6-0-stearoyl-
1.61 g of N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine are obtained. Melting point 185-187°
C (decomposition). [α], →-21.8° (C-0.5° water, 3 days later) Elemental analysis value C45HtsNeO1s・CH#OOH・
H2O and shite calculation value (%) G 56.00. H
8,77, N 8.71 Analysis value (%) C55,99
,H8,76,N 8.76Example 5 By reacting in substantially the same manner as in Example 4, 11penzyloxycarbonyl-N" (1-α-〇-benzyl-N
-acetylmuramyl-alanyl-D-inglutaminyl)-lysine methyl ester 1.509(l-penzyloxycarbonyl)'-NE-(1-(1-0-he>cyl-6-0-stearoyl-N -acetylmuramyl-alanyl-D-inglutaminyl)-lysine methyl ester is obtained, melting point 204-205°C (min #).
(α) +44.41’ (G −0,9、り1:1
1:Iホルム)。(α) +44.41' (G -0.9, ri 1:1
1: Iform).
元素分析値 C5cnH92N60ts4)L+Oとし
て計算値(%) C62,46,H8,26,N 7
.40分析値C%) c 62.41. H8,2
2,N 7.+4上記化合物1.189を接触還元反応
に付し。Elemental analysis value C5cnH92N60ts4) Calculated value (%) as L+O C62,46,H8,26,N 7
.. 40 analysis value C%) c 62.41. H8,2
2, N 7. +4 The above compound 1.189 was subjected to catalytic reduction reaction.
白色粉末としてN’−(6−0−ステアロイル−N−ア
セチルムラミル−アラニル−D−イソグルタミニル)−
リジンメチルエステル0.45gを得る。融点174〜
176.5°C(分解)。N'-(6-0-stearoyl-N-acetylmuramyl-alanyl-D-isoglutaminyl)- as a white powder
0.45 g of lysine methyl ester is obtained. Melting point 174~
176.5°C (decomposition).
〔α)p+zo、o’ (c−o、e、水、2日後)0
元素分析値 C44Hs o Ns O+ s ・GH
,+C0OH−H2Oとして計算値(%) C56,
42,H8,85,N 8.58分析値(支)) c
56.21. H8,74,N 8.45実施例6
N’−(6−o−ステアロイル−N−アセチルムラミル
−アラニル−D−イソグルタミニル)−リジン0.80
りにN、 N−ジメチルホルムアミド60−を加える。[α) p+zo, o' (co, e, water, 2 days later) 0
Elemental analysis value C44Hs o Ns O+ s ・GH
, +C0OH-H2O calculated value (%) C56,
42, H8, 85, N 8.58 analysis value (support)) c
56.21. H8,74,N 8.45 Example 6 N'-(6-o-stearoyl-N-acetylmuramyl-alanyl-D-isoglutaminyl)-lysine 0.80
Add N,N-dimethylformamide 60- to the solution.
水冷攪拌下酢酸のN−ヒドロキシ−5−ノルボルネン2
.8−ジカルボキシイミド活性エステル0.209.N
−メチルモルホリン0.09−を加え、30分後室温に
戻し。N-Hydroxy-5-norbornene 2 in acetic acid under stirring under water cooling
.. 8-dicarboximide active ester 0.209. N
-Methylmorpholine 0.09- was added and the temperature was returned to room temperature after 30 minutes.
2日間攪拌する。反応の進行が十分でない為。Stir for 2 days. This is because the reaction is not progressing sufficiently.
反応液を水冷下さらに酢酸のN−ヒドロキシ−5−フル
ボルネン2.3−ジカルボキシイミド活性エステル0.
209.N−メチルモルボリン0.09−を加え、徐々
に室温に戻し2日間反応する。反応液を減圧濃縮し、残
留物にエーテル100−を加える。析出する沈殿を濾取
し、約40°Cの温水に溶解し2強酸性イオン交換樹脂
ダウエックス50(H”)通す。通液を凍結乾燥するこ
とにより白色粉末としてl−アセチル−Ne−(6−0
−ステアロイル−N−アセチルムラミル−アラニル−D
−イソグルタミニル)−リジン0.747を得る。融点
191.5〜193℃(分解)。〔α)D+25.3°
(c−o、5.酢酸:H2O−50’ 2+ 2日後
)。The reaction solution was cooled with water and further mixed with N-hydroxy-5-fulbornene 2,3-dicarboximide active ester of acetic acid.
209. Add 0.09% of N-methylmorboline, gradually warm to room temperature, and react for 2 days. The reaction solution was concentrated under reduced pressure, and ether 100- was added to the residue. The precipitate is collected by filtration, dissolved in warm water at about 40°C, and passed through a strongly acidic ion exchange resin Dowex 50 (H"). The solution is freeze-dried to form a white powder, l-acetyl-Ne-( 6-0
-stearoyl-N-acetylmuramyl-alanyl-D
-isoglutaminyl)-lysine 0.747 is obtained. Melting point 191.5-193°C (decomposed). [α)D+25.3°
(c-o, 5. Acetic acid: H2O-50' 2+ after 2 days).
元素分析値 C45HaoNso1rH20として計算
値じン C57,06,H8,7,9,N 8.87分
析値(%) C56,81,H8,48,N 9.0
5実施例7
1−アセチル−N’−(6−0−ステアロイル−N−ア
セチルムラミル−アラニル−D−イングルタミニル)−
リジンO,aOりを10−のメタノールに溶解し、ジア
ゾメタン−エーテル溶液を加える。30分後9石油エー
テルを加え。Elemental analysis value Calculated value as C45HaoNso1rH20 Jin C57,06,H8,7,9,N 8.87Analysis value (%) C56,81,H8,48,N 9.0
5 Example 7 1-Acetyl-N'-(6-0-stearoyl-N-acetylmuramyl-alanyl-D-inglutaminyl)-
Dissolve lysine O, aO in 10-methanol and add diazomethane-ether solution. After 30 minutes, add 9 petroleum ether.
析出する結晶を濾取する。次いでメタノール−エーテル
−n−ヘキサンから再結晶することにより一−アセチル
ーN’−(6−0−ステアロイル−N〜ルアセチルムラ
ミルアラニル−D−イソグルタミニル)−リジンメチル
エステル0.219を得る。融点202.5〜208.
5°C(分解)。〔α〕。+25.3°(G−0,6,
酢酸−水−50:2,2日後)。The precipitated crystals are collected by filtration. Then, recrystallization from methanol-ether-n-hexane yields 1-acetyl-N'-(6-0-stearoyl-N-acetylmuramylalanyl-D-isoglutaminyl)-lysine methyl ester 0.219. Melting point 202.5-208.
5°C (decomposition). [α]. +25.3° (G-0,6,
Acetic acid-water-50: 2.2 days later).
元素分析値 C45HszNaO14・1+H20とし
て計算値(%) c 56.95. H8,88,
N 8.66分析値赴) C57,12,H8,64
,N 8.88参考例
脂肪酸の活性エステルの調製
脂肪酸LOmmoleをテトラヒドロフラン1〇−に溶
解し、水冷攪拌下、ジシクロへキシルカルボジイミド2
06Tn9及びN−ヒドロキシ−5−ノルボルネン−2
,8−ジカルボキシイミド179WI9を加える。30
分後、徐々に室温に戻し約5時間反応する。析出したジ
シクロヘキシル尿素を渡来し、濾液を濃縮する。乾燥エ
ーテルを加えて不溶物を濾去後、濾液を減圧濃縮乾固す
ると脂肪酸のN−ヒドロキシ−5−ノルボルネン−2,
8−ジカルボギシイミド活性エステル体の白色結晶が得
られる。Elemental analysis value Calculated value (%) as C45HszNaO14・1+H20 c 56.95. H8,88,
N 8.66 analysis value) C57,12, H8,64
, N 8.88 Reference Example Preparation of active ester of fatty acid Dissolve fatty acid LOmmole in 10-tetrahydrofuran, and add dicyclohexylcarbodiimide 2-
06Tn9 and N-hydroxy-5-norbornene-2
, 8-dicarboximide 179WI9. 30
After a few minutes, the mixture was gradually returned to room temperature and reacted for about 5 hours. The precipitated dicyclohexyl urea is removed and the filtrate is concentrated. After adding dry ether and filtering off insoluble matter, the filtrate was concentrated to dryness under reduced pressure to obtain the fatty acid N-hydroxy-5-norbornene-2,
White crystals of 8-dicarbogyshiimide active ester are obtained.
Claims (1)
aはアラニンを意味し、Rは水素原子、アルキル基又は
アラルキル基を、nは1〜6の整数を+ Al及びA2
は各々水素原子又は炭素原子数2〜30の分校を有する
こともある飽和もしくは不飽和脂肪酸残基を意味する。 )[Claims] Muramyl represented by the general formula is a peptide derivative (Al in the above formula
a means alanine, R is a hydrogen atom, an alkyl group or an aralkyl group, n is an integer of 1 to 6 + Al and A2
means a saturated or unsaturated fatty acid residue which may each have a hydrogen atom or a branch of 2 to 30 carbon atoms. )
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58047458A JPS59172497A (en) | 1983-03-22 | 1983-03-22 | Novel muramyl peptide derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58047458A JPS59172497A (en) | 1983-03-22 | 1983-03-22 | Novel muramyl peptide derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS59172497A true JPS59172497A (en) | 1984-09-29 |
Family
ID=12775709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58047458A Pending JPS59172497A (en) | 1983-03-22 | 1983-03-22 | Novel muramyl peptide derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59172497A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5519236A (en) * | 1978-07-27 | 1980-02-09 | Dai Ichi Seiyaku Co Ltd | Muramyl dipeptide derivative |
JPS5528933A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
JPS5528932A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Novel muramyldipeptide derivative |
JPS5618996A (en) * | 1979-06-21 | 1981-02-23 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide derivative |
JPS5649396A (en) * | 1979-09-28 | 1981-05-02 | Dai Ichi Seiyaku Co Ltd | Novel muramyldipeptide derivative |
-
1983
- 1983-03-22 JP JP58047458A patent/JPS59172497A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5519236A (en) * | 1978-07-27 | 1980-02-09 | Dai Ichi Seiyaku Co Ltd | Muramyl dipeptide derivative |
JPS5528933A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
JPS5528932A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Novel muramyldipeptide derivative |
JPS5618996A (en) * | 1979-06-21 | 1981-02-23 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide derivative |
JPS5649396A (en) * | 1979-09-28 | 1981-05-02 | Dai Ichi Seiyaku Co Ltd | Novel muramyldipeptide derivative |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0014984B1 (en) | Glucosamine-peptide derivatives, their production and use | |
EP0021367B1 (en) | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | |
US4216208A (en) | N-Acyl derivatives of glucosamines having antitumor chemotherapeutic activity | |
JPH02500275A (en) | Methods and compositions for the prevention of ulcers | |
CA1056818A (en) | Process for the manufacture of dipeptide derivatives | |
EP0015468A1 (en) | 6-Deoxyglucosamine-peptide derivatives, their production and use | |
JPS638119B2 (en) | ||
SU1346046A3 (en) | Method of producing h-butyl ethers derivatives of n-acetylmuramylpeptides | |
JPH0243727B2 (en) | ||
JPS59172497A (en) | Novel muramyl peptide derivative | |
JPS61100564A (en) | Peptide-substituted heterocyclic immunostimulants | |
JPH0414120B2 (en) | ||
HU180894B (en) | Process for producing pharmaceutically acceptable salts of 3-square bracket-bracket-s-bracket closed-1-comma above-phenyl-ethyl-amino-square aracket closed-propylamino-bleomycine | |
CS207607B2 (en) | Method of making the 1-n-/omega-amino-alphe-hydroxyalcanoylcanamycine a and b | |
EP0048613B1 (en) | 4-0-substituted -2-deoxystreptamine aminoglycoside derivatives, their preparation and formulations containing them | |
US4666887A (en) | Intravenous or intraperitoneal administration of a tripeptide compound for treating cancer | |
JPH0245640B2 (en) | ||
JPS59164799A (en) | Muramic acid amide derivative | |
Suli-Vargha et al. | Synthesis and antitumor activity of N-terminal proline-containing peptide-(chloroethyl) nitrosoureas | |
JPS6312879B2 (en) | ||
KR840000010B1 (en) | Method of preparing for muranyldipeptide derivatives | |
EP0050856B1 (en) | New peptide, process for its preparation and pharmaceutical composition containing it | |
US4594416A (en) | 2-β-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production | |
KR920000694B1 (en) | Method for producing dipeptide derivatives | |
KR830002873B1 (en) | Method of preparation for alkyl-ketahexopyrandside derivatives |